Market Overview:
The global insulin detemir market is expected to grow at a CAGR of 6.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of diabetes, rising awareness about diabetes and its treatment, and technological advancements in insulin delivery devices. Based on type, the global insulin detemir market can be segmented into reusable and disposable products. The disposable product segment is expected to grow at a higher CAGR than the reusable product segment during the forecast period from 2018 to 2030. This growth can be attributed to factors such as increasing preference for convenience and hygiene among consumers and growing demand for minimally invasive procedures. Based on application, the global insulin detemir market can be divided into hospital use, clinic use, home use, and other applications.
Product Definition:
Insulin detemir is a long-acting insulin analog. It is used to control blood sugar in people with diabetes mellitus.
Resuable:
Insulin detemir is a long-acting analog of human insulin, which was approved by the U.S. FDA in 2003 for treatment of diabetic patients who are unable to maintain an adequate blood glucose level through oral intake and have not achieved satisfactory results with short-term (6 months) therapy with regular human insulin.
Disposable:
A disposable insulin pen is a device used to deliver rapid-acting insulin through injection sites. They are available in various sizes and can be used with Novo Nordisk or any other brand of insulin. Disposable pens are intended for one-time use and should be disposed after use, as they pose an increased risk of infection due to their lack of sterilization procedures.
The global disposables market size was valued at USD 1,37 billion in 2016.
Application Insights:
The global insulin detemir market has been segmented on the basis of application into hospital, clinic, home use, and others. The hospital segment dominated the market in terms of revenue in 2017. This is primarily due to a high prevalence of diabetes and an increasing number of hospitals across the globe that are adopting advanced healthcare technologies for better management of diabetes. For instance, as per U.S Department Health Resources & Services Administration (HHS), there were approximately 3 million people with diabetes in 2015; out-of-hospital delivery was estimated at around 2 million while about 1 million received care at home or another setting outside hospitals for their type 2 diabetes treatment needs. Thus, from a business standpoint it makes sense to deploy such devices and services at hospitals owing to higher patient volumes which can be effectively managed thereby driving demand for insulin detemir over the forecast period.
Regional Analysis:
North America dominated the global insulin detemir market in 2017 due to the presence of major players, availability of advanced medical products, and high healthcare expenditure. Moreover, increasing incidence diabetes is expected to boost demand for insulin delivery devices such as pumps & patches over the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising disposable income coupled with improving healthcare infrastructure in emerging countries such as China and India. Furthermore, an increase in awareness regarding new technologies used for diabetes management is also expected drive regional market growth during the estimated time span.
Insulin detemir has been approved by regulatory agencies for marketing.
Growth Factors:
- Increasing prevalence of diabetes mellitus: The global prevalence of diabetes is increasing rapidly and is expected to reach 642 million by 2040. This will create a large pool of patients who will require insulin therapy, thereby driving the demand for insulin detemir.
- Rising awareness about diabetes and its treatment: There is an increasing awareness among people about diabetes and its treatment options. This is leading to an increase in the number of people who are being prescribed insulin detemir for the management of their condition.
- Technological advancements in Insulin Delivery Devices: There has been a significant advancement in technology with respect to Insulin Delivery Devices in recent years, which has made them more user-friendly and easier to use. This is likely to boost the adoption rate of insulin detemir among patients worldwide.
Scope Of The Report
Report Attributes
Report Details
Report Title
Insulin Detemir Market Research Report
By Type
Resuable, Disposable
By Application
Hospital, Clinic, Home Use, Others
By Companies
Novo Nordisk, MNKD, Bristol-Myers Squibb Company, Emisphere, Biocon
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
249
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Insulin Detemir Market Report Segments:
The global Insulin Detemir market is segmented on the basis of:
Types
Resuable, Disposable
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Home Use, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novo Nordisk
- MNKD
- Bristol-Myers Squibb Company
- Emisphere
- Biocon
Highlights of The Insulin Detemir Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Resuable
- Disposable
- By Application:
- Hospital
- Clinic
- Home Use
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Insulin Detemir Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Insulin detemir is a type of insulin used to lower blood sugar in people with diabetes. It is a long-acting insulin that works for about 24 hours after it is injected.
Some of the major companies in the insulin detemir market are Novo Nordisk, MNKD, Bristol-Myers Squibb Company, Emisphere, Biocon.
The insulin detemir market is expected to grow at a compound annual growth rate of 6.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Insulin Detemir Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Insulin Detemir Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Insulin Detemir Market - Supply Chain
4.5. Global Insulin Detemir Market Forecast
4.5.1. Insulin Detemir Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Insulin Detemir Market Size (000 Units) and Y-o-Y Growth
4.5.3. Insulin Detemir Market Absolute $ Opportunity
5. Global Insulin Detemir Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Insulin Detemir Market Size and Volume Forecast by Type
5.3.1. Resuable
5.3.2. Disposable
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Insulin Detemir Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Insulin Detemir Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinic
6.3.3. Home Use
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Insulin Detemir Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Insulin Detemir Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Insulin Detemir Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Insulin Detemir Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Insulin Detemir Demand Share Forecast, 2019-2026
9. North America Insulin Detemir Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Insulin Detemir Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Insulin Detemir Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinic
9.4.3. Home Use
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Insulin Detemir Market Size and Volume Forecast by Type
9.7.1. Resuable
9.7.2. Disposable
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Insulin Detemir Demand Share Forecast, 2019-2026
10. Latin America Insulin Detemir Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Insulin Detemir Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Insulin Detemir Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinic
10.4.3. Home Use
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Insulin Detemir Market Size and Volume Forecast by Type
10.7.1. Resuable
10.7.2. Disposable
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Insulin Detemir Demand Share Forecast, 2019-2026
11. Europe Insulin Detemir Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Insulin Detemir Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Insulin Detemir Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinic
11.4.3. Home Use
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Insulin Detemir Market Size and Volume Forecast by Type
11.7.1. Resuable
11.7.2. Disposable
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potenial Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Insulin Detemir Demand Share, 2019-2026
12. Asia Pacific Insulin Detemir Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Insulin Detemir Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Insulin Detemir Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinic
12.4.3. Home Use
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Insulin Detemir Market Size and Volume Forecast by Type
12.7.1. Resuable
12.7.2. Disposable
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Insulin Detemir Demand Share, 2019-2026
13. Middle East & Africa Insulin Detemir Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Insulin Detemir Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Insulin Detemir Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinic
13.4.3. Home Use
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Insulin Detemir Market Size and Volume Forecast by Type
13.7.1. Resuable
13.7.2. Disposable
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Insulin Detemir Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Insulin Detemir Market: Market Share Analysis
14.2. Insulin Detemir Distributors and Customers
14.3. Insulin Detemir Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Novo Nordisk
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. MNKD
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Bristol-Myers Squibb Company
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Emisphere
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Biocon
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
